Date clarification: DuPont is officially scheduled to release Q2 results at 6:00 a.m. ET today, Tuesday, August 4, 2026, followed by its conference call at 8:00 a.m. ET—not tomorrow. (dupont.com)
This should be less about whether DuPont can edge past a tightly guided Q2 number and more about whether management can validate the second-half growth, margin, and cash-flow story.
The company entered the quarter with momentum: Q1 organic sales rose 2%, operating EBITDA increased 15%, and transaction-adjusted free cash flow improved to $147 million. Management then raised full-year guidance. (investors.dupont.com)
The key questions are:
DuPont implemented a 1-for-3 reverse stock split on June 24, so investors should use split-adjusted EPS figures. The company translated its previous Q2 EPS guidance of approximately $0.59 into approximately $1.75, and its full-year range into $7.02–$7.16. (investors.dupont.com)
| Metric | Company Q2 guidance | Public consensus / reference point |
|---|---|---|
| Revenue | Approximately $1.80B | Approximately $1.81B–$1.82B |
| Operating EBITDA | Approximately $430M | Company guide is the primary benchmark |
| EBITDA margin | Approximately 23.9% | Down modestly from 24.6% in Q1 |
| Adjusted EPS, split-adjusted | Approximately $1.75 | Approximately $1.76 |
| Organic sales growth | Approximately 3% | Company assumption |
Public estimate aggregators cluster around $1.76 of adjusted EPS and $1.81–$1.82 billion of revenue, leaving expectations essentially aligned with management’s guidance. (tipranks.com)
Implication: A small EPS beat alone probably will not be enough. The stock’s reaction should depend more heavily on organic growth quality, margins, and the full-year outlook.
Management guided Healthcare & Water Technologies to mid-single-digit Q2 organic growth, led by medical devices, biopharma, and industrial water. In Q1, Healthcare grew at a high-single-digit organic rate, with strength in medical packaging and biopharma. (s23.q4cdn.com)
Investors should look for:
A continuation of mid- to high-single-digit Healthcare growth would reinforce the argument that post-separation DuPont deserves a higher-quality specialty-materials multiple.
Water organic sales declined in Q1 because of Middle East logistics disruption and project timing. Approximately $10 million of delayed Q1 shipments had already shipped in April, while management expected Water to be roughly flat in the first half and accelerate in the second half as large industrial and desalination projects come through. (s23.q4cdn.com)
The important questions are:
A weak Q2 Water result accompanied by another promise of second-half recovery would lower confidence in the full-year organic-growth target.
DuPont estimated approximately $90 million of incremental input costs associated with the Middle East environment and planned to offset these costs through pricing and surcharges. Approximately $25 million of Q2 pricing was expected, although management acknowledged that the timing mismatch between price and cost would create roughly a 30-basis-point Q2 margin headwind. Mix was expected to create another roughly 40-basis-point sequential headwind. (s23.q4cdn.com)
That explains why EBITDA margin is guided to approximately 23.9%, versus 24.6% in Q1.
A constructive result would show:
A margin below roughly 23.5%, absent a clear timing explanation, would be a meaningful disappointment.
DuPont expects low-single-digit organic growth in Diversified Industrials. Aerospace and automotive—particularly EV battery-adhesive wins—have been the primary supports, while North American residential construction has remained weak. Printing and packaging were expected to improve from a soft Q1. (s23.q4cdn.com)
Watch for:
If construction remains weak but segment margin holds near 23%, that would still be a respectable operational result.
Current full-year guidance calls for:
The Q2 guide implies first-half operating EBITDA of approximately $844 million, or roughly 48% of the full-year midpoint. That leaves a second half requiring approximately $900 million of EBITDA, supported by Water project timing, fuller price realization, productivity, and normal seasonal improvement. (s23.q4cdn.com)
Maintaining guidance would be acceptable, provided management expresses confidence in Water and price-cost execution. A modest raise would be clearly positive. A reduction caused by project delays, inflation, or construction weakness would challenge the post-separation rerating thesis.
DuPont received approximately $1.1 billion of net cash proceeds from the Aramids sale and announced a $275 million accelerated repurchase after previously completing a $500 million ASR. That leaves substantial capacity under its $2 billion authorization. Management has also indicated interest in healthcare-related acquisitions while targeting leverage around 2x. (s23.q4cdn.com)
Investors should listen for:
A disciplined combination of buybacks and smaller, growth-accretive Healthcare deals would likely be received better than a large acquisition requiring meaningful leverage.
DD closed at $141.31 on August 3, down roughly 4% from its May 5 post-Q1 close and about 8% below its May peak. At that price, the stock trades at approximately 19.9 times the midpoint of DuPont’s split-adjusted 2026 EPS guidance.
That is not an obviously low multiple. It suggests the market already assigns value to DuPont’s improved portfolio, healthcare exposure, margin expansion, and capital returns. Consequently, a result merely in line with guidance may produce a muted reaction unless management also raises expectations or improves the qualitative outlook.
The Q2 numbers themselves have a relatively narrow expectation range. The more important issue is whether DuPont can prove that its second-half plan remains intact.
The strongest report would combine continued Healthcare momentum, a Water rebound, controlled price-cost pressure, and a modest guidance increase. Conversely, if Water recovery slips or margins weaken despite the announced pricing actions, investors may question whether the approximately 20x earnings valuation already discounts too much of DuPont’s post-separation improvement.